Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (3527)	8/1/1999 10:45:00 PM
From: BDR	Respond to of 10280

<BTW, "The Campaign for Fair Pharmaceutical Competition" is apparently funded by ... the generic manufacturers. > I am shocked. Shocked!(g)

To: Biomaven who wrote (3527)	8/2/1999 9:46:00 AM
From: quidditch	Read Replies (1) \| Respond to of 10280

So, if SGP is supposed to file a NDA for desloratadine by year end, should we care whether this bill passes or fails? Yes we should. Delaying generic Claritin increases the value of all SEPR's antihistamines. As long as we're into the "Sepracorpse", "I've never felt so horrible in my life" and "it's more of a love/hate thing", as to which sentiments I can safely vouch sharing in varying degree, is there, in the brutal, take no prisoners, dark shadows of corporate spin and short-term bottom line thuggery, a plausible case to be made for the cynical notion that if generic Claritin is delayed, then so might SGP's filing of the NDA for desloratadine? I am aware of SGP's announced intentions. But corporate PR is easily capable of manufacturing "reasons". Hoping not. Steven